Home > Insider Trading > Filing (0001209191-20-025990)

Filing Details

Accession Number:: 0001209191-20-025990
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2020-04-28 17:13:55
Reporting Period:: 2020-04-24

Accepted Time:: 2020-04-28 17:13:55
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1796280	Oric Pharmaceuticals Inc.	ORIC	()	DE

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1055951	Orbimed Advisors Llc	601 Lexington Avenue 54Th Floor New York NY 10022		Yes	No	Yes	No
1682115	Orbimed Capital Gp Vi Llc	601 Lexington Avenue 54Th Floor New York NY 10022		Yes	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2020-04-24	281,250	$16.00	281,250	No	4	P	Indirect	See footnotes
Common Stock	Acquisiton	2020-04-28	1,875,000	$0.00	2,156,250	No	4	C	Indirect	See footnotes
Common Stock	Acquisiton	2020-04-28	373,356	$0.00	2,529,606	No	4	C	Indirect	See footnotes
Common Stock	Acquisiton	2020-04-28	236,111	$0.00	2,765,717	No	4	C	Indirect	See footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See footnotes
No	4	C	Indirect	See footnotes
No	4	C	Indirect	See footnotes
No	4	C	Indirect	See footnotes

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series B Preferred Stock	Disposition	2020-04-28	1,875,000	$0.00	1,875,000	$0.00
Common Stock	Series C Preferred Stock	Disposition	2020-04-28	373,356	$0.00	373,356	$0.00
Common Stock	Series D Preferred Stock	Disposition	2020-04-28	236,111	$0.00	236,111	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect

Footnotes

The shares are held of record by by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the general partner of OPI VI and OrbiMed Advisors LLC ("Advisors") is the managing member of GP VI. By virtue of such relationships, GP VI and Advisors may be deemed to have voting power and investment power over the securities held by OPI VI and as a result, may be deemed to have beneficial ownership over such securities. Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by OPI VI.
This report on Form 4 is jointly filed by Advisors and GP VI. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Carl L. Gordon ("Gordon"), a member of Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose.
Each of the Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date.